BMT CTN Protocol 1501

A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease

Below are protocol-related documents, which may be periodically updated.

            Protocol Co-Chair: Joseph Pidala, MD, PhD

            Protocol Co-Chair: Margaret MacMillan, MD

            Protocol Officer: Mehdi Hamadani, MD        

            Protocol Coordinator: Terry Pritchard, MS        

This study reached its accrual goal on February 16, 2018 and is now closed to new patient enrollment.